Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Naddafi, Fatemeh, Davami, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644525/
https://www.ncbi.nlm.nih.gov/pubmed/26629482
_version_ 1782400665852575744
author Naddafi, Fatemeh
Davami, Fatemeh
author_facet Naddafi, Fatemeh
Davami, Fatemeh
author_sort Naddafi, Fatemeh
collection PubMed
description CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating CD19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. Moreover, several anti- CD19 mAbs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.
format Online
Article
Text
id pubmed-4644525
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-46445252015-12-01 Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy Naddafi, Fatemeh Davami, Fatemeh Int J Mol Cell Med Review Article CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating CD19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. Moreover, several anti- CD19 mAbs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far. Babol University of Medical Sciences 2015 /pmc/articles/PMC4644525/ /pubmed/26629482 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Naddafi, Fatemeh
Davami, Fatemeh
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title_full Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title_fullStr Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title_full_unstemmed Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title_short Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
title_sort anti-cd19 monoclonal antibodies: a new approach to lymphoma therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644525/
https://www.ncbi.nlm.nih.gov/pubmed/26629482
work_keys_str_mv AT naddafifatemeh anticd19monoclonalantibodiesanewapproachtolymphomatherapy
AT davamifatemeh anticd19monoclonalantibodiesanewapproachtolymphomatherapy

Ejemplares similares